LinkedIn: We are pleased to announce that a late-breaking abstract on BYN-002 has been accepted for presentation and publication at UEG Week 2026.
The abstract, entitled: “BYN-002 (TL-001), A Next-Generation Anti-TL1A Antibody Demonstrating Potent Neutralization, Extended Pharmacokinetics, Durable TL1A Suppression and Favorable Immunogenicity: Interim Phase 1 SAD/MAD Results,” will be presented as an e-poster during the congress.